Overview

Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis) using the EyeGate® II Iontophoresis system in patients with dry eye.
Phase:
Phase 3
Details
Lead Sponsor:
Eyegate Pharmaceuticals, Inc.
Treatments:
BB 1101
Citric Acid
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Ophthalmic Solutions
Pharmaceutical Solutions
Sodium Citrate